However, in comparison to optimally dosed anti-CTLA4 mAb administered via LDDS to tbLN, PD1 blockade was found to result in marginally weaker tumor inhibition as is evidenced by its relatively higher ex vivo luciferase activity, normalized in vivo luciferase activity and lower complete response rate and overall survival (Fig. 6 A – D). The gene discussed is CTLA4; the disease is neoplasm.